Partow Kebriaei Selected Research

FM 100 (FM100)

1/2019	Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.
1/2019	Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma.
10/2013	A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Partow Kebriaei Research Topics

Disease

65	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 04/2024 - 07/2003
51	Neoplasms (Cancer) 02/2024 - 09/2008
40	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 02/2024 - 04/2007
33	Graft vs Host Disease (Graft-Versus-Host Disease) 02/2024 - 04/2007
31	Multiple Myeloma 05/2024 - 06/2006
28	Philadelphia Chromosome 04/2024 - 07/2003
21	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 02/2024 - 04/2007
17	Leukemia 10/2023 - 01/2005
16	Hematologic Neoplasms (Hematological Malignancy) 11/2023 - 03/2013
14	B-Cell Lymphoma (Lymphoma, B Cell) 11/2023 - 01/2020
13	Residual Neoplasm 12/2023 - 07/2003
13	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2021 - 05/2004
9	Chromosome Aberrations (Chromosome Abnormalities) 01/2023 - 12/2002
8	Non-Hodgkin Lymphoma (Lymphosarcoma) 12/2023 - 06/2009
8	Hodgkin Disease (Hodgkin's Disease) 01/2022 - 11/2012
7	Lymphoma (Lymphomas) 01/2019 - 06/2009
5	Disease Progression 02/2024 - 07/2013
5	Pathologic Complete Response 07/2020 - 09/2010
4	Myeloid Leukemia (Leukemia, Myelocytic) 10/2023 - 06/2011
4	Infections 01/2023 - 05/2015
4	Hemorrhage 01/2023 - 12/2015
4	Cytokine Release Syndrome 12/2021 - 01/2020
4	Sepsis (Septicemia) 01/2021 - 01/2019
3	Melanoma (Melanoma, Malignant) 01/2023 - 01/2022
3	Acute Lung Injury 01/2021 - 01/2019
3	Blast Crisis (Blast Phase) 01/2021 - 03/2011
3	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 01/2020 - 02/2017
3	Body Weight (Weight, Body) 01/2020 - 12/2012
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 11/2017 - 03/2013
2	Primary Myelofibrosis (Myelosclerosis) 12/2023 - 01/2020
2	Exanthema (Rash) 01/2023 - 01/2021
2	Venous Thromboembolism 01/2022 - 01/2021
2	COVID-19 12/2021 - 01/2021
2	Cytopenia 10/2021 - 01/2020
2	cell-associated neurotoxicity 01/2021 - 01/2020
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2021 - 09/2008
2	Thrombocytopenia (Thrombopenia) 01/2021 - 01/2021
2	Ascites 01/2020 - 01/2020
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2020 - 01/2018
2	Mucositis 05/2019 - 11/2017

Drug/Important Bio-Agent (IBA)

30	Chimeric Antigen ReceptorsIBA 01/2024 - 10/2010
22	Busulfan (Busulfex)FDA Link 12/2023 - 03/2011
18	fludarabineIBA 12/2023 - 04/2007
17	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2024 - 01/2009
15	Melphalan (Alkeran)FDA LinkGeneric 01/2022 - 04/2007
12	Tyrosine Kinase InhibitorsIBA 11/2023 - 07/2007
11	Inotuzumab OzogamicinIBA 02/2024 - 06/2013
11	AntigensIBA 01/2023 - 06/2011
9	Tacrolimus (Prograf)FDA LinkGeneric 12/2023 - 04/2007
8	Imatinib Mesylate (Gleevec)FDA Link 08/2013 - 07/2003
7	Methotrexate (Mexate)FDA LinkGeneric 12/2023 - 04/2007
7	axicabtagene ciloleucelIBA 11/2023 - 01/2020
7	SteroidsIBA 01/2022 - 01/2016
6	Lenalidomide (CC 5013)FDA Link 10/2023 - 06/2009
6	HLA Antigens (Human Leukocyte Antigens)IBA 01/2023 - 06/2011
6	blinatumomabIBA 01/2023 - 10/2018
5	Clofarabine (Clolar)FDA Link 01/2022 - 06/2011
5	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 01/2009
5	Vincristine (Oncovin)FDA LinkGeneric 01/2021 - 01/2009
5	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 08/2017 - 01/2010
5	Dasatinib (BMS 354825)FDA Link 12/2016 - 09/2010
4	ponatinibIBA 04/2024 - 01/2021
4	HLA-A Antigens (HLA-A)IBA 01/2023 - 06/2011
4	BilirubinIBA 01/2023 - 04/2012
4	Rituximab (Mabthera)FDA Link 01/2021 - 09/2008
4	CytokinesIBA 01/2021 - 01/2005
4	Monoclonal AntibodiesIBA 09/2020 - 05/2012
3	Transaminases (Aminotransferases)IBA 01/2023 - 04/2012
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2023 - 05/2010
3	Mycophenolic Acid (Cellcept)FDA LinkGeneric 12/2021 - 11/2016
3	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2021 - 07/2009
3	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 01/2009
3	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 12/2020 - 01/2018
3	FM 100 (FM100)IBA 01/2019 - 10/2013
3	Cytarabine (Cytosar-U)FDA LinkGeneric 08/2017 - 02/2016
2	Alkylating AgentsIBA 02/2024 - 08/2017
2	Azacitidine (5 Azacytidine)FDA Link 02/2024 - 05/2009
2	Interleukin-15 (Interleukin 15)IBA 01/2024 - 11/2016
2	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 11/2023 - 01/2020
2	Peptides (Polypeptides)IBA 01/2023 - 01/2022
2	Bortezomib (Velcade)FDA Link 01/2022 - 01/2022
2	venetoclaxIBA 01/2021 - 01/2020
2	ofatumumab FDA Link 01/2021 - 07/2020
2	Calcineurin InhibitorsIBA 12/2020 - 05/2015
2	tisagenlecleucelIBA 11/2019 - 01/2019

Therapy/Procedure

70	Therapeutics 04/2024 - 07/2003
58	Hematopoietic Stem Cell Transplantation 05/2024 - 04/2007
54	Stem Cell Transplantation 05/2024 - 07/2007
41	Cell Transplantation 11/2023 - 03/2013
38	Transplantation 12/2023 - 06/2006
34	Drug Therapy (Chemotherapy) 11/2023 - 06/2006
12	Immunotherapy 11/2023 - 05/2010
9	Homologous Transplantation 11/2021 - 05/2009
6	Salvage Therapy 01/2023 - 07/2007
5	Radiotherapy 01/2023 - 06/2009
4	Aftercare (After-Treatment) 11/2021 - 09/2008
4	Haploidentical Transplantation 12/2019 - 02/2017
4	Investigational Therapies (Experimental Therapy) 11/2016 - 06/2012
3	Autologous Transplantation 01/2024 - 11/2019
2	Critical Care (Surgical Intensive Care) 01/2021 - 01/2020